Clinical Trials Logo

Clinical Trial Summary

This is a prospective study that will conduct a series of focus groups with non-Hispanic Black and Hispanic childhood cancer survivors to obtain their input on culturally adapting a mobile CBT program for chronic pain and tDCS procedures. Once this adaptation process is completed, the investigators will conduct a feasibility trial with non-Hispanic Black, Hispanic and non-Hispanic White childhood cancer survivors of bone sarcoma with chronic pain. The feasibility study will assign eligible participants to either culturally adapted mobile CBT + active tDCS to the dorsolateral prefrontal cortex or culturally adapted mobile CBT + sham tDCS. We anticipate approximately 60 participants for the focus groups and approximately 30 participants for the feasibility study for a total of about 90 participants.


Clinical Trial Description

Survivors of pediatric bone sarcoma are at-risk for developing chronic pain. Cognitive behavioral therapy (CBT) is an effective non-pharmacologic treatment for chronic pain, and can be delivered remotely to reduce access barriers. However, these programs have not been adapted to be culturally sensitive to underserved populations thus limiting their reach, usefulness, and uptake. The investigators propose to culturally tailor an established, evidence-based mobile CBT program for chronic pain to Black and Hispanic adolescent survivors of childhood cancer. Once the program is fully adapted, we propose to pair the culturally adapted mobile CBT program with remotely delivered transcranial direct current stimulation (tDCS), which may enhance pain control in survivors. The investigators will conduct a 6-week feasibility study in a racially/ethnically diverse sample of non-Hispanic White, non-Hispanic Black, and Hispanic adolescent survivors of pediatric bone sarcoma with chronic pain using culturally adapted CBT paired with remote tDCS. Study results will inform the development of a randomized clinical trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05746429
Study type Interventional
Source St. Jude Children's Research Hospital
Contact Tara Brinkman, PhD
Phone 901-595-3300
Email tara.brinkman@stjude.org
Status Recruiting
Phase N/A
Start date April 6, 2023
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05621668 - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Phase 1
Not yet recruiting NCT05515068 - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Active, not recruiting NCT00592293 - Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas N/A
Recruiting NCT05051059 - Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients N/A
Recruiting NCT06129903 - Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma N/A
Completed NCT06202599 - Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Recruiting NCT04634227 - Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Early Phase 1
Recruiting NCT03277924 - Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Phase 1/Phase 2
Active, not recruiting NCT03462316 - NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma Phase 1
Recruiting NCT04055220 - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas N/A
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Completed NCT02301039 - SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Phase 2
Recruiting NCT06409013 - Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT04181970 - Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Completed NCT00525057 - Dalteparin in Preventing DVT in Participants With Cancer N/A
Recruiting NCT04698785 - Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients Phase 2
Completed NCT01588522 - Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease Phase 1
Terminated NCT03468075 - Gemcitabine Plus Ascorbate for Sarcoma in Adults Phase 2